Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 3,847 shares at $23.38 ($90K) on 2026-07-30, disclosed to the SEC on 2026-07-30.
Open-market sale of $90k NRIX by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| NRIX | SELL | 2026-08-05 | $100K | — | Filing → |
| NRIX | SELL | 2026-08-05 | $109K | — | Filing → |
| NRIX | SELL | 2026-06-25 | $108K | — | Filing → |